Pharsight

Osphena generic

Osphena is an anti-menopausal drug owned by Duchesnay. It was first authorized for market use on 26 February 2013. The drug contains the active ingredient ospemifene and comes in tablet;oral dosage. Osphena is protected by a total of 8 patents, out of which one has expired.

When will Osphena generic be available?

The generic version of Osphena is expected to become available after 09 July 2028, when the last patent expires. The drug area where the patents apply includes methods to enhance the bioavailability of Ospemifene and solid formulations of the drug, which are patented till 2026 and 2028 respectively.

Osphena uses

Osphena is primarily used in the treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. It uses the active ingredient ospemifene, which is administered orally with food to enhance bioavailability, to treat these symptoms. The drug also helps to treat dyspareunia associated with menopause.

Osphena patent expiration

Osphena is covered by 8 patents with the last patent set to expire on 09 July 2028. The remaining patents primarily concern the methods to enhance the bioavailability of Ospemifene and the solid formulations of the drug. All these factors together determine the expected release date of Osphena generic. Below are the details of the patent:

Litigations filed on Osphena

Osphena dosage

Want to ask something?